Open Access

ASCVD & residual risk: recent clinical insights with icosapent ethyl.

Topic: Lipid-Lowering Agents
Organised by PACE-CME - Supported by an unrestricted educational grant from Amarin Pharma

Congress Session

About the speaker

Professor Deepak Bhatt

Harvard Medical School, Boston (United States of America)
36 presentations
2 followers

4 more presentations in this session

Introduction.

Speaker: Professor L. Badimon (Barcelona, ES)

Thumbnail

A continuum of multifactorial benefits of icosapent ethyl.

Speaker: Professor M. Back (Stockholm, SE)

Thumbnail

Integrating icosapent ethyl in clinical practice: which patients will benefit?

Speaker: Professor S. Verma (Toronto, CA)

Thumbnail

Discussion.

Speaker: Professor L. Badimon (Barcelona, ES)

Thumbnail

Access the full session

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Speakers: Professor D. Bhatt, Professor L. Badimon, Professor M. Back, Professor S. Verma, Professor L. Badimon
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk